Словачка - Словачки - ŠÚKL (Štátny ústav pre kontrolu liečiv)

recordati industria chimica e farmaceutica s.p.a., taliansko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Словачка - Словачки - ŠÚKL (Štátny ústav pre kontrolu liečiv)

recordati industria chimica e farmaceutica s.p.a., taliansko - leuprorelín - 56 - hormona (lieČiva s hormonÁlnou aktivitou)

Европска Унија - Словачки - EMA (European Medicines Agency)

virbac s.a. - osaterón acetát - urologika - psy - liečba benígnej hypertrofie prostaty (bph) u mužských psov.

Европска Унија - Словачки - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degarelix - prostatické nádory - endokrinná terapia - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Европска Унија - Словачки - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatické nádory - endokrinná terapia - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Европска Унија - Словачки - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatické nádory - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Европска Унија - Словачки - EMA (European Medicines Agency)

janssen-cilag international n.v. - abiraterón acetátu - prostatické nádory - endokrinná terapia - zytiga je uvedená s prednizónom alebo prednisolone na:liečbu metastatickým kastrácia odolný proti rakovine prostaty u dospelých mužov, ktorí sú bez príznakov alebo mierne symptomatických po poruche androgén deprivácie terapia, pri ktorej chemoterapia nie je zatiaľ klinicky indicatedthe liečbu metastatickým kastrácia odolný proti rakovine prostaty u dospelých mužov, ktorých choroba pokročila na alebo po docetaxel založené chemoterapia režim.

Европска Унија - Словачки - EMA (European Medicines Agency)

krka, d.d., novo mesto - abiraterón acetátu - prostatické nádory - endokrinná terapia - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Европска Унија - Словачки - EMA (European Medicines Agency)

accord healthcare s.l.u. - abiraterón acetátu - prostatické nádory - endokrinná terapia - abiraterone accord is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicatedthe treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel based chemotherapy regimen.

Европска Унија - Словачки - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - imunologické prístroje pre sviňovité - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. Ďalším kľúčovým prispievateľom k odrôd chlpov, skatole, môže byť tiež znížený ako nepriamy účinok. agresívne a sexuálne (montážne) správanie sa tiež znižuje. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).